Due to health issues, this site is no longer maintained and will be shut down shortly.


Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver worldwide. It offers diagnostic solutions in various therapeutic areas, such as metabolic diseases, liver diseases, non-alcoholic steato-hepatitis, cholestatic liver diseases, inflammation and autoimmune diseases, and inflammatory bowel diseases. The company's pipeline product comprises Elafibranor, biomarkers, TGFTX1, and TGFTX4. Genfit SA was founded in 1999 and is headquartered in Loos, France.This company has ADRs that trade in the U.S. as the symbol GNFT.

3.68 EUR
As of 03/24/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  France
Country of incorporation:  France
IPO date:  12/19/2006
Stock exchange:    Euronext Paris
Exchange country:   France
Market cap:   171,265,680 EUR
Current dividend yield:   0.00%
Sedol:      B03B708

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy